For Daniil Boiko and Andrei Tyrin, the thought for Onepot AI got here from the similar frustration.
“The greatest concepts in drug discovery have been usually blocked not by biology, however by synthesis,” Boiko advised TechCrunch. Synthesis is the creation of recent molecules through the use of chemical reactions. It’s like a recipe or Lego items, the place small items, elements, molecules, come collectively to kind a wider puzzle image, a meals dish, a bigger molecule.
As one would possibly anticipate, it’s fairly arduous to create these small molecules that go on to construct greater ones.
For Boiko, a Ph.D. candidate finding out machine studying in chemistry at Carnegie Mellon (he acquired his bachelor’s and grasp’s in natural chemistry from a college in Russia), that meant realizing that drug hunters — the scientists who oversee drug discovery and growth — have been skipping promising concepts simply because the chemical molecules to create the medicine appeared too arduous to make.
“The compounds by no means even acquired an opportunity to be examined,” Boiko advised TechCrunch.
For Tyrin (who acquired his bachelor’s in laptop science at MIT), his time working on drug discovery computational pipelines made him notice how behind the world of drug discovery was. “The fashions might generate concepts in hours, but it surely might take months for the lab to catch up,” he advised TechCrunch.
“We each noticed that the world was throwing cash into molecular design and virtually ignoring the tougher drawback of really making the molecules,” Boiko stated. However there was a geopolitical angle too, he continued, international provide chains have gotten susceptible, and the U.S. is getting into a commerce battle and progressive competitors, as soon as once more, with China.
Techcrunch occasion
San Francisco
|
October 13-15, 2026
“It was clear,” Boiko stated. “Small molecule synthesis wanted to be rebuilt from the floor up in the United States.”
Boiko and Tyrin got here collectively to create Onepot, an organization that’s residence to the small-molecule synthesis lab POT-1. In addition they constructed Phil, an AI natural chemist, to assist run experimental evaluation to extend the course of of compound synthesis for their early industrial companions. These companions are biotech and pharma firms which are at present attempting out their expertise.
On Wednesday, the firm got here out of stealth with $13 million of funding, together with pre-seed cash, and a seed spherical led by Fifty Years.
“At the moment, pharma and biotech firms both construct complete groups of chemists in-house or work with contract analysis organizations abroad,” Tryin stated of the course of for molecular synthesis. Human chemists can spend months of analysis to create even a single compound, at a price of hundreds of {dollars}.
It includes numerous trial and error — finding out numerous compounds, gathering information on organic exercise, how the drug strikes by means of the physique, toxicology experiences, and developing with what to experiment with subsequent. “The major limiting issue right here will not be testing these compounds, however making them in the first place,” Tyrin continued. “We goal to compress this all the way down to days.”
Tyrin stated the product is fairly simple. Onepot has a listing of molecules it might make. Purchasers select which compounds it need and then Onepot’s expertise will synthesize the molecules and then ship them to the buyer so the buyer can use them in their very own experiments. (They ship bodily merchandise both as dry compounds of options in plates or vials).
The backend of the product is the place Boiko and Tyrin have enjoyable, dissecting the issues of chemical synthesis to seek out out which mixtures of molecules work collectively. They constructed a lab the place they’re letting LLM brokers entry these so-called molecule recipes for coaching so the brokers can even discover out what works and doesn’t in compound constructing.
“When executing experiments in the lab, we seize each single element that goes into the course of,” Tyrin stated — which means tracing temperature and, basically, the elements that have been added to a combination to create compounds. “No info is misplaced, which makes experiences reproducible even when somebody decides to run them in ten years from now.”
This additionally means their brokers generate hypotheses from real-world experiments moderately than literature information, usually mined from the web.
Boiko referred to as the fundraising course of “hectic,” and stated they met their lead investor by means of an intro. “What was speculated to be a brief assembly was a multi-hour whiteboard session about industrializing synthesis,” Boiko stated. Others in the spherical embrace Khosla Ventures, Speedinvest, OpenAI co-founder Wojciech Zaremba and Google’s Chief Scientist Jeff Dean.
The recent capital might be used to construct a second lab in San Francisco so the workforce can tackle extra clients. It should additionally broaden the workforce and its compound discovery engine. On the service facet, Boiko and Tyrin take a look at WuXi AppTec and Enamine as rivals.
Total, Boiko and Tyrin hope to make drug discovery at the least two instances sooner and hopefully change the notion of what’s attainable after one faucets into the “bizarre” chemistry that scientists as soon as thought was off limits.
“You’re not simply rushing up drug discovery, you’re increasing the design area for what medicine and supplies will be,” Boiko stated. “That drug that we haven’t found but, could be out there, ready for us to seek out it.”